ArticlePharmaceutical research2022

Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib.

René J Boosman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.